For example, Loxo-195 is a recently developed drug, which phase 1/2 of the study started in 2017 in patients with TRK-positive solid tumors and TRK fusion-positive cancers (clinical trials NCT03215511 and NCT03206931). The gene discussed is NTRK1; the disease is cancer.